Ludlow Research has placed an “earnings watch” on ScripsAmerica, a supplier of prescription, OTC, and nutraceutical drugs in North America, as the company prepares to report its fiscal 2012 financial results.
Ludlow Research forecasts that ScripsAmerica’s financial performance will reflect slow to moderate growth for full-year 2012, stemming from expiring and renewing contracts during the 12-month period.
For 2013, the equities research firm forecasts that ScripsAmerica will record strong revenues for the current quarter and remainder of the year. These estimates are based, in part, on ScripsAmerica’s monthly revenue for January 2013, during which the company achieved record revenue of $904,275. Additionally, the company recorded revenue of $849,039 in February 2013, representing a year-over-year increase of 115 percent.
Ludlow Research says ScripsAmerica is on pace to achieve more than $10 million in revenue for fiscal 2013, representing an annual growth rate of more than 50 percent compared to full-year 2012.
ScripsAmerica’s own projections, which are in line with Ludlow Research estimates, are supported by the anticipated product launch of its RapiMed® pediatric pain and fever reliever and acquisition of its pharmaceutical repackager, Marlex Pharmaceuticals.
To view the full report, and access risks, disclosures, and potential outlook visit: www.wallstreetnewscast.com/profile/scrc.html
For more information visit www.ScripsAmerica.com
Let us hear your thoughts below: